Portland, OR — 11/09/2017 — Postmenopausal vaginal atrophy (PVA) refers to reduction in estrogen production after menopause and this condition is also called as vaginal atrophy. Less estrogen leads to thinning, drying, and decreased elasticity of vaginal tissues. Various other factors that lead to decrease in estrogen levels include perimenopause during breast feeding, surgical menopause, pelvic radiation therapy, and chemotherapy.
Presence of favorable healthcare reforms, high unmet medical needs across emerging economies, and gradual shift from systemic estrogen treatments, such as vaginal gels, and patches, to non-estrogenic therapies drive the market. In addition, rise in prevalence of postmenopausal vaginal atrophy further accelerates the market growth. However, low diagnosis rate, and risk associated with the existing treatment options restricts the market.
Get the sample copy of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/4378
The report segments the global PVA market based on therapy type and drug forms. Based on therapy type, the market is categorized into estrogen-based drugs (Premarin, Vagifem, Estrace, Estring and Femring) and non-estrogen-based drugs (BZA/CE, Osphena, and Vaginorm). Based on drug forms, the market is categorized as vaginal gels, creams, tablets, rings, and patches. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Make a purchase enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/4378
The key players operating in the global PVA market include Actavis plc, Bionovo, Inc., Endoceutics, Inc., Novo Nordisk A/S, Pfizer Inc., Teva Pharmaceuticals Ltd., Therapeutics MD, Inc., Shionogi & Company, Limited, Allergan plc, and Shionogi & Co. Ltd.
Postmenopausal Vaginal Atrophy Drugs Market Key Segments:
By Therapy Type
By Drug Form